Marshall Wace, LLP Delcath Systems, Inc. Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
A detailed history of Marshall Wace, LLP transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 86,665 shares of DCTH stock, worth $685,520. This represents 0.0% of its overall portfolio holdings.
Number of Shares
86,665
Previous 130,425
33.55%
Holding current value
$685,520
Previous $542,000
23.8%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding DCTH
# of Institutions
40Shares Held
7.37MCall Options Held
143KPut Options Held
60.8K-
Aigh Capital Management LLC Baltimore, MD2.36MShares$18.7 Million4.54% of portfolio
-
Vivo Capital, LLC Palo Alto, CA1.67MShares$13.2 Million1.06% of portfolio
-
Bvf Inc San Francisco, CA1.2MShares$9.51 Million0.17% of portfolio
-
Vanguard Group Inc Valley Forge, PA684KShares$5.41 Million0.0% of portfolio
-
Cibc World Market Inc. Toronto, A6260KShares$2.06 Million0.0% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $68M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...